Kathryn K. Oi

Kathryn K. Oi

Auto-generated profile, based on publicly available information

Kathryn K. Oi

University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Science Advances
Verified
Journal Article
Open access
MSMatthias Schuster
Matthias Schuster
EBEmile Brabet
Emile Brabet
KOKathryn K. Oi
Kathryn K. Oi
NDNicolas Desjonquères
Nicolas Desjonquères
KMKerstin Moehle
Kerstin Moehle
OZOliver Zerbe
Oliver Zerbe
The rise of antimicrobial resistance poses a substantial threat to our health system, and, hence, development of drugs against novel targets is urgently needed. The natural peptide thanatin kills Gram-negative bacteria by targeting proteins of the lipopolysaccharide transport (Lpt) machinery. Using the thanatin scaffold together with phenotypic medicinal chemistry, structural data, and a target-focused approach, we developed antimicrobial peptides with drug-like properties. They exhibit potent activity against Enterobacteriaceae both in vitro and in vivo while eliciting low frequencies of resistance. We show that the peptides bind LptA of both wild-type and thanatin-resistant Escherichia coli and Klebsiella pneumoniae strains with low-nanomolar affinities. Mode of action studies revealed that the antimicrobial activity involves the specific disruption of the Lpt periplasmic protein bridge.